Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Merck & Co Inc V.MRK


Primary Symbol: MRK

Healthcare
Merck & Co., Inc. is a global health care company. It offers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company’s Pharmaceutical segment includes human health pharmaceuticals and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. It sells these human health pharmaceutical products to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, and health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. The Company’s lead candidate, MK-6070, is a T-cell engager targeting delta-like ligand 3 (DLL3), an inhibitory canonical Notch ligand.


NYSE:MRK - Post by User

Merck & Co Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Post by diamondfields98on May 31, 2010 9:54am
337 Views
Post# 17142779

Grades!!!

Grades!!!New to Merc and to stockhouse but looking at some of the historical grades on Merc you begin to realize the explosive potential that this property holds.....

D04-354...504g/t over .67m
D04-360...63.48g/t over 10.5m
D04-361...32g/t over 11.25m
D05-375...33g/t over 3.6m

Compared to the other junior plays out there with much larger market caps(and much lower grades and intervals) then you would assume at some point the stock price will reflect the value. Go MERC Go!
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities